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Dr Craig Miller (Stanford, Calif). For those of you who don’t
know, Nimesh Desai is a Canadian surgeon who went across the
border to Philadelphia for advanced cardiovascular surgical train-
ing. He is going to join the staff at Penn in July. This was a nice
presentation with a lot of information, which has generated in
my mind a lot of questions. I think you are Eastern Canadian,
right? Ontario?
Dr Desai. Yes.
Dr Miller. First, especially with respect to those survival
curves, your numbers are fairly robust out to 3 to 4 years, but I
wish you would have amputated everything beyond that time be-
cause you just don’t have enough patients remaining at risk to sup-
port meaningful inferences. The median follow-up was 25 months,
so this is really a short-term follow-up study, albeit still valuable.
That is a word of caution.The Journal of Thoracic and CaNumber two, it is a heterogeneous substrate that has both
strengths and weaknesses. Most would say that is a weakness,
and you may be comparing apples with prunes with tomatoes.
Conversely, I think there are some strengths to be derived from
this heterogeneous substrate. Number one, the most compelling
good news here is something we hoped for in October 1996
when Michael Dake and I did our first thoracic aortic stent graft
for acute complicated type B dissection (our early experience
was subsequently published in 1999, or 10 years ago): Thoracic
aortic stent grafts are going to save more lives in the very sick pa-
tients with acute complicated type B dissection than they are in any
of the other pathologic subsets. That goes against traditional think-
ing, but I think your data have demonstrated this clearly. Although
none of the clinically available stent grafts in the United States are
approved by the Food and Drug Administration for this indication
(it is all off-label), this application is probably where TEVAR is
going to prove to be the most life-saving. It is also a topic that
has never been tested in a randomized clinical trial. Patients with
acute (<14 days) type B dissection are now being randomized in
Germany and Scandinavia in the ADSORB trial comparing TE-
VAR with best medical therapy, but patients with complicated
acute type B are excluded, so there is more to be learned.
Now, what about the negatives of the heterogeneous substrate?
For example, for your hybrid arch cases, the results aren’t pretty.
On the basis of your analysis, where should you change your prac-
tice and abandon or give up stent grafting? Your results are not
unique because all hybrid thoracoabdominal and hybrid arch TE-
VAR results are poor, and this hybrid approach is rapidly being
abandoned by most authorities. How can we get these patients to
a center that can reproducibly perform a relatively safe and durable
open surgical arch or open thoracoabdominal repair? There are
many hospitals in the United States where the thought of putting
a patient on the pump and cooling them down for profound hypo-
thermic circulatory arrest for total arch or thoracoabdominal aortic
replacement is analogous to being sent to the gas chamber in San
Quentin prison. Of course this is not true in other centers that have
special expertise and are very experienced. The advocates for con-
tinuing hybrid arch procedures just don’t get this point, and in their
hands they can’t do open repairs with reasonably low risk. How do
we get the patients away from centers like that, or will they con-
tinue what you have tried where it doesn’t work very well? Or, al-
ternatively, where should we say that doing nothing is the most
prudent option for these very old and high risk patients? At Stan-
ford we continue to stand by our statement 5 years ago that asymp-
tomatic patients who are judged inoperable for open aortic graft
replacement because of multiple other medical problems should
not be offered TEVAR because treatment will not improve quality
of life and their 5-year life expectancy is dismal secondary to the
other comorbidities.
Dr Desai. I want to thank Dr Miller for his comments. He has
been a thought leader in our field of aortic surgery and cardiac sur-
gery in general for a long time.
With regard to hybrid procedures, as Dr KariyanaMilewski pre-
sented fromour groupat theAmericanAssociation of Thoracic Sur-
gery this year, we don’t see a benefit in doing hybrid procedures for
arch surgery in what I would still call higher risk but younger pa-
tients, those aged less than70years.Our data showed that in patients
aged more than 70 years who are also high risk for other reasons,rdiovascular Surgery c Volume 142, Number 3 593
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thoughwe don’t really knowwhat their long-term survivalwould be
without any procedure at all. This brings up another point, which is
when we compare all of this technology with itself, using different
indications, or other open operations, we have overlooked the big-
gest control group, which is the medically treated group. Our ap-
proach in terms of offering hybrid arch operations today is in the
person who is prohibitively high risk only. It is our experience
that it is not an ideal solution in a younger patient, even though it
may be a ‘‘less invasive’’ or a more convenient operation, particu-
larly for practitioners who are not trained to use circulatory arrest.
Dr Miller. You described 2 other substrates where the results
are not so good, probably because the patients are sicker. That is
one thing that has changed over the last 10 years: You are pushing
the envelope, taking on cases today you wouldn’t have even
dreamed about stent grafting 10 years ago. One of these subsets
is acute traumatic aortic transection. You only had 16 in this series,
and the results were not good in terms of paraplegia, early death,
and late death. I assume they all had TEVAR because you were
forced to do something (eg, rupture or other life-threatening major
complication). If these patients have multiple other injuries and no
life-threatening emergency complication related to the aorta, we
need to remember there remains a role for expectant negative ino-
tropic, controlled hypotension management followed by elective
open surgical graft replacement weeks or even months later.
Have you backed off emergency TEVAR for your acute aortic
tear cases? Believe it or not, not every patient has to be treated
with an emergency stent graft, a practice that unfortunately is be-
coming popular around the world. The long-term durability of TE-
VAR in these patients who generally are very young is dubious at
best. If you don’t have a life-threatening emergency right under
your nose, what about treating them medically, stabilizing them,
get them to where you can do a more definitive and durable
open operation with minimal risk?
Dr Desai. In younger patients, that is our preferred approach, to
stabilize them medically and perform an open operation when it is
appropriate. It is only in the truly emergency salvage case that we
have been performing TEVAR for a transaction.
Dr Miller. Those are wise words, which I hope all the audience
heard.
Next, when you threw a stent graft into the downstream thoracic
aorta like a frozen elephant trunk in the patients with acute type A
dissection, it also did not work out very well. Has your enthusiasm
for this at the time of open ascending and total arch surgical re-
placement waned in view of the high morbidity and mortality? Ob-
servational data exist demonstrating that doing something in the
downstream thoracic aorta, either with a surgical elephant trunk
graft (as Dr Kazui advocated in patients with Marfan syndrome)
or a stent graft, does not decrease the need for late reoperation
nor increase survival. Has your approach changed on the basis of
this analysis?
Dr Desai. I believe it was at the Southern Thoracic Surgical As-
sociation meeting this year that Dr Pochettino from our group pre-
sented our data on the hybrid type A repair, or so-called frozen
elephant-trunk type A repair. Our initial belief is that this proce-
dure has a future, that we have been able to show there is less di-
latation of the proximal descending thoracic aorta. We have also594 The Journal of Thoracic and Cardiovascular Surgshown it does increase the risk of paraplegia, which is not minor,
and I think this is actually an ideal question to be answered with
a randomized clinical trial, more so than almost any other group
of patients who will undergo TEVAR.
DrMiller. That is a good thought. For now, there is a substantial
price the patient must pay to do so, both in terms of early death and
paraplegia, and the rationale for doing so is based on a notion that
is not proven.
What about the paraplegia risk? It really concerned me to hear
you say that extent of descending thoracic aortic coverage (your
term is extent C coverage from the left subclavian artery to the di-
aphragm) has no apparent adverse effects or increases in the risk of
spinal cord injury. When Frank Criado first published his results
showing that the probability of spinal cord injury increases mark-
edly as one covers more descending aorta with TEVAR, most sur-
geons promptly backed off, and I think patients benefited. But are
you now telling me that with cerebrospinal fluid drainage and other
adjuncts there no longer is an additive adverse risk? I am con-
cerned about that, and I would urge all of us to be cautious, pre-
serve whatever intercostal artery blood flow you can, and not get
carried away with TEVAR covering excessive lengths of descend-
ing aorta. Please note that this admonition does not apply to using
noncovered bare metal stents or the petticoat stent on a Cook TX2
dissection TEVAR system, which ‘‘paves’’ the distal true lumen
down below the stent graft that has covered the primary intimal
tear. We at Stanford like that distal adjunctive approach, but we re-
ally have to do everything we can to minimize the likelihood of
spinal cord injury. Do you still think it is safe to cover large lengths
of descending thoracic aorta?
Dr Desai. It has always been our approach to cover as little as
necessary to get a seal, so in a type B dissection case, for instance,
we do not aim to pave the whole aorta. We will try to cover the en-
try tear, reexpand the true lumen at the most proximal area, but not
bring it all theway down to the celiac access except in cases of rup-
ture. With aneurysm cases, again we try to ensure that we are in
good landing zones for seal but not to cover more than that unless
it is necessary. We do not recommend extending coverage because
it is safe.What we are saying is that in our data set with the patients
we operated on we did not see a difference. Now that may be be-
cause we have had a very proactive group of cardiac anesthetists
and neurologists working with us who are involved in taking
care of neurologic changes in the intensive care unit, which may
not be the case in other centers. There is a complex interaction
among patient-related factors, the original aortic pathology, revas-
cularization of the subclavian when covered, and anatomic consid-
erations, such as previous abdominal aortic aneurysm repair, that
affect whether a patient has a postoperative problem with spinal
cord ischemia. There are a lot of issues there, but in our data set
with our approach we did not see a difference.
Dr Miller. How many times did you actively revascularize the
left subclavian artery before, during, or after TEVAR?
Dr Desai. It varies by indication. In our current experience, any
situation where we are going to cover the left subclavian electively
wewill bypass as a routine onanypatient except in true emergencies.
DrMiller. That is good to hear, and we strongly concur. Thanks
for coming out to the 2009 Western Thoracic Surgical Association
meeting in Alberta, Nimesh.ery c September 2011
